José A. Karam

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• 5x-Multiplier Versus 3-Tier Model

  Annals of Surgery · 2026-06-20

• TKI resistance is associated with immune dysfunction in ccRCCPreprint

  Research Square · 2026-06-14

• IP59-15 POSTOPERATIVE SURVEILLANCE IN NON-CLEAR CELL RENAL CANCER: IS CURRENT PRACTICE BEST PRACTICE?

  The Journal of Urology · 2026-04-27

• IP84-06 DEREGULATION OF SPINDLE ASSEMBLY CHECKPOINTS VIA TRIP13 UPREGULATION LEADS TO LOSS OF HETEROZYGOSITY IN AGGRESSIVE CHROMOPHOBE RENAL CELL CARCINOMA AND MAY BE A PROMISING THERAPEUTIC TARGET

  The Journal of Urology · 2026-04-27

• p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors

  Cancer Cell · 2026-01-31

• Genomic and Epigenomic Signatures Can Distinguish Aggressive Chromophobe Renal Cell Carcinoma from Indolent Renal Oncocytic Tumors in Clinical-grade Samples

  European Urology Oncology · 2025-11-05

• Data from Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma

  2025-11-03

• Table S2 from Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma

  2025-11-03

• Figure S4 from Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma

  2025-11-03

• Figure S3 from Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma

  2025-11-03

• Figure S1 from Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma

  2025-11-03

• Figure S2 from Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma

  2025-11-03

• Table S1 from Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma

  2025-11-03

• 7Phase 2 trial of metastasis directed radiotherapy without systemic therapy (MRWS) for oligometastatic clear cell renal cell carcinoma (ccRCC) and investigation of circulating tumor DNA (ctDNA)

  The Oncologist · 2025-10-01

• Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial

  The Lancet Oncology · 2025-09-04 · 15 citations

• High-Dose Chemotherapy for Multiply or Poor-Risk Relapsed Germ Cell Tumors

  Clinical Cancer Research · 2025-08-25 · 2 citations

• Temporal Trends and Socioeconomic Determinants of Cytoreductive Nephrectomy Utilization for Metastatic Renal Cell Carcinoma in the USA

  European Urology Focus · 2025-08-20 · 1 citations

• Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank

  Urologic Oncology Seminars and Original Investigations · 2025-08-18 · 2 citations

• Risk Factors for First-Year Recurrence in Patients With Synchronous Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy and Complete Metastasectomy

  The Journal of Urology · 2025-08-05

• Impact of Active Surveillance on Nephrometric Scores of Bosniak III and IV Renal Cysts

  International Journal of General Medicine · 2025-08-01